Source comparison
CJC-1295 No DAC & Ipamorelin: Research Comparison
Plasma Half-Life ~30 minutes ~2 hours Staggered (30 min / 2 hr) Combination preserves pulsatility without tonic elevation. Ideal for studying physiological GH dynamics Primary Mechanism GHRH receptor agonism (cAMP pathway) Ghrelin receptor agonism (calcium mob
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- ~2 hours
- Staggered (30 min / 2 hr)
- Combination preserves pulsatility without tonic elevation. Ideal for studying physiological GH dynamics
- Primary Mechanism
- GHRH receptor agonism (cAMP pathway)
- Ghrelin receptor agonism (calcium mobilisation)
- Dual pathway (cAMP priming + calcium release)
- Mechanistic complementarity produces synergistic pulse amplitude increase without receptor desensitization
- Mean GH Pulse Amplitude (vs Baseline)
- 1.6× baseline
- 2.1× baseline
- 2.8× baseline
- Synergy exceeds additive prediction. Suggests priming effect where GHRH receptor activation potentiates ghrelin receptor signaling
- Pulse Duration Extension
- +19 minutes (rodent models)
- No significant extension
- +19–23 minutes
- GHRH pathway controls pulse duration; ghrelin pathway controls amplitude. Combination modulates both independently
- Cortisol / Prolactin Elevation
- None detected
- Selective GH pathway activation without stress hormone involvement. Critical for chronic study designs
- Feedback Suppression Risk
- Low (pulse-preserving)
- Preserves endogenous pulsatility unlike exogenous GH, which suppresses pituitary secretion via negative feedback
- The bottom-line clinical interpretation: CJC-1295 No DAC and Ipamorelin represent complementary pharmacological tools for researchers studying GH pulse architecture. Monotherapy provides isolated pathway modulation; combination therapy produces synergistic amplitude enhancement with preserved physiological rhythm.